A Study of ARRY-502 in Patients With Persistent Asthma

Trial Profile

A Study of ARRY-502 in Patients With Persistent Asthma

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Mar 2014

At a glance

  • Drugs ARRY 502 (Primary)
  • Indications Allergic asthma
  • Focus Therapeutic Use
  • Sponsors Array BioPharma
  • Most Recent Events

    • 04 Mar 2014 Results presented at the 70th Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
    • 23 Jul 2013 Top-line results reported in an Arrray BioPharma media release.
    • 23 Jul 2013 Primary endpoint 'Forced-expiratory-volume-in-1-second' has been met, according to an Arrray BioPharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top